Doxycycline in Type II Diabetes

Phase 1

Recruiting

• Conditions: Diabetes Mellitus, Type 2
• Interventions: Drug: Sitagliptin 100mg; Drug: Doxycyclin

• Registration Number: NCT06329882
• Lead Sponsor: Mostafa Bahaa

Brief Summary

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-03-09
• Study First Submitted QC: 2024-03-24
• Study First Posted: 2024-03-26
• Study Start: 2024-03-30
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-03
• Last Update Posted: 2025-04-04
• Primary Completion: 2026-03-20
• Study Completion: 2026-04-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5

Exclusion Criteria

• Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Comparative group	Sitagliptin 100mg	patients were on sitagliptin 100mg /day monotherapy plus doxycycline 100 mg
Comparative group	Doxycyclin	patients were on sitagliptin 100mg /day monotherapy plus doxycycline 100 mg
control group	Sitagliptin 100mg	patients were on sitagliptin 100mg /day monotherapy

Primary Outcome Measures

Name	Time	Method
Change in glycemic profile	3 months	measurement of glycated hemoglobin

Trial Locations

Locations (1)

Tanta Unuversity; 🇪🇬 Tanta, Egypt